Illumina Sees Q1 Orders Rise for Exome, Cyto, and Methylation Chips amid Decline in Array Instruments | GenomeWeb

Demand remains strong for at least some of Illumina's microarray portfolio, as the company said this week that sales of certain chips contributed to a spike in consumable revenues during the first quarter.

At the same time, Illumina saw microarray instrumentation sales decrease in Q1, causing total array revenue to decline year-over-year, contributing to a 3 percent drop in total revenues compared to the first quarter of 2011.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: parent-of-origin effects, framework to uncover clinically important mutations from whole genome sequence data, and more.

A survey of Cincinnati schoolchildren finds teenagers want to know their genetic predisposition to disease, LiveScience reports.

More and more universities are helping their researchers patent their inventions, the Los Angeles Times reports.

Cancer Research UK unveils seven 'grand challenges' that it will fund researchers to tackle.